ClinicalTrials.gg
WithdrawnNCT03726281Updated Aug 21, 2019

Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors

A Phase 2 interventional study of Nivolumab in Germ Cell Tumors, sponsored by Hospital Beatriz Ângelo. Withdrawn at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-21.

Sponsored by Hospital Beatriz Ângelo · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Why this study was withdrawn
End of Agreement between BMS and SGHL

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To assess the clinical activity of nivolumab monotherapy, as measured by the investigator-assessed clinical benefit rate (CBR), in patients with platinum-recurrent or platinum-refractory metastatic germ cell tumors (GCT). CBR is defined by sum of complete responses (CR), partial responses (PR) and stable disease (SD) for at least 3 months, with stable or declining tumor markers (αFP and HCG), using Response Evaluation Criteria In Solid Tumors (RECIST 1.1).

Read the detailed description

For patients with testicular GCT, there is no consensus on the most effective treatment for men who relapse after first-line chemotherapy for advanced disease, between salvage conventional cisplatin-based dose chemotherapy and high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell rescue (ASCT). A significant number of patients with recurrent metastatic testicular GCT can still be cured with salvage chemotherapy but long term survival becomes negligible for cisplatin-refractory disease or for patients beyond second relapse. HDCT with ASCT should be considered for patients with recurrent metastatic disease, at least beyond second relapse, although its therapeutic impact has not yet been proven in randomized controlled trials. In contrast, patients with platinum-refractory metastatic GCT and those with recurrent primary mediastinal nonseminomatous GCT (PMNSGCT) are rarely cured by conventional dose salvage chemotherapy.

Immunotherapy with anti-PD-1 and anti-PD-L1 antibodies have demonstrated clinical activity in multiple malignancies, with durable remissions and long-term survivors in patients with metastatic malignant melanoma, non-small cell lung cancer and renal cell cancer, and are being studied in several other tumor types. In GCT a recent study identified PD-L1 expression in 73% of all seminomas and in 64% of all non-seminomas. Patients with low PD-L1 expression had significantly better progression-free survival (PFS) and OS compared to patients with high PD-L1 expression. Frequent expression of PD-L1 in testicular GCT suggests that these patients may benefit from checkpoint inhibitor treatment with anti-PD-1 or anti-PD-L1 antibodies. So far there are only case reports of nine patients with GCT treated with immune check-point inhibitors. One patient, initially diagnosed with metastatic melanoma but subsequently reclassified as non-seminomatous GCT, was treated with a single dose of nivolumab and experienced clinical resolution of lymphadenopathy, decrease in serum tumor markers and a 47% tumor burden reduction by immune-related response criteria. Another report includes seven patients treated with checkpoint inhibitors (nivolumab or pembrolizumab) as a compassionate use off-label treatment attempt for highly-pretreated GCT. Four patients died shortly after beginning treatment due to tumour progression, the remaining three patients received treatment for at least 6 months and long-term tumor response was achieved in two of the three, both of them with tumors highly positive for PD-L1 staining. Another case report was published of a man with a poor-risk nonseminomatous GCT who had disease progression after HDTC/ASCT and had a durable response to immune checkpoint inhibitor.

Recently a single arm phase II trial of pembrolizumab in patients with incurable platinum refractory GCT was presented at ASCO Annual Meeting 2017. This was the first reported trial evaluating immune checkpoint inhibitors in GCT, enrolling 12 male patients age ≥ 18 with metastatic GCT that had progressed after first line cisplatin-based chemotherapy and after at least 1 salvage regimen (CDCT or HDCT). All patients had non-seminoma, the primary tumor site was testis in 11 patients and mediastinum in 1 patient. 5 patients had late relapse (> 2 years) and 6 patients had received prior HDCT. No partial or complete responses were observed, 2 patients achieved radiographic stable disease for 12 and 9 weeks but with continuing rise of AFP, suggesting that Pembrolizumab has no clinically meaningful activity in refractory GCT.

Thus, with limited and conflicting data, further studies with immune checkpoint inhibitors in patients with recurrent metastatic GCT are required.

02

Conditions studied

  • Germ Cell Tumors
03

In context

Neoplasms, Germ Cell and Embryonal

167 studies on the registry are indexed under Neoplasms, Germ Cell and Embryonal; 49 are open to participants now.

Browse Neoplasms, Germ Cell and Embryonal studies →

Lead sponsor

Hospital Beatriz Ângelo is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Male or female, aged 18 years
  • GCT, seminoma or non-seminoma, previously treated with standard doublet or triplet cisplatin-containing chemotherapy for metastatic disease in: a) second or further relapse from primary testicular, retroperitoneal or ovarian GCT; b) first or further relapse of PMNSGCT; c) primary- GCT (defined as progression within 8 weeks of finishing chemotherapy for advanced GCT); or d) "late relapse" (> 2 years after cisplatinum-containing chemotherapy for metastatic GCT) that is not amenable to surgical resection.
  • (ECOG) performance status of 0 or 2.
  • Evidence of recurrent disease by imaging (CT or MR) or rising tumor markers (αFP or HCG). NOTE: If a rising tumor marker is the only evidence of progressive disease, at least 2 consecutive rising values at least one week apart are needed and alternative causes of increased serum levels of these markers must be excluded (cross reaction with luteinizing hormone (LH) (that can be tested if needed by testosterone suppression of LH), liver disease, use of marijuana, or second primary tumor)
  • Received initial cisplatin based combination therapy, such as BEP, EP, VIP, or similar regimens AND, for primary testicular or ovarian GCT, progression after at least one 'salvage' chemotherapy regimen (such as, TIP, VeIP, VIP or high dose chemotherapy with ).
  • "Failure" of prior therapy is defined as: a >20% increase in the sum of the longest diameter of target lesions during prior therapy which is not amenable to surgical resection; the presence of new tumor lesions that are not amenable to surgical resection; an increase in αFP or HCG (two separate determinations at least one week apart are required if rising tumor markers are the only evidence of treatment failure) in patients with metastatic disease. NOTE: Patients with clinically growing "teratoma" (normal or declining tumor markers and radiographic progression) should be considered for surgery.
  • Use an adequate method of starting with the first dose of study therapy through 5 months after the last dose of study therapy.
  • according to v1.1 obtained by imaging within 28 days prior to registration.
  • Non-measurable but evaluable disease associated increasing tumor markers (αFP and HCG) may be eligible, upon review by two PIs.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an , anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  • History of allergy or to study drug components.
  • Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the patient to receive protocol therapy, or interfere with the interpretation of study results.
  • Patients with an active, known or suspected disease.
  • Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol.
  • Patients with a condition requiring systemic treatment with either (>10 mg daily prednisone equivalent) or other medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
  • Diagnosis of immunodeficiency or current treatment with systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  • Known history of active Tuberculosis, (HIV) or active (i.e. HBsAg reactive) or (i.e. HCV RNA [qualitative] is detected).
  • Treatment with a within 30 days of planned start of study therapy. NOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (i.e. Flu-Mist®) are live attenuated vaccines, and are not allowed.
  • Treatment with chemotherapy, targeted small molecule therapy or radiation therapy within 3 weeks prior to study Day 1 or without recovery (ie. ≤ Grade 1) from AEs from such previously administered agents. Patients with alopecia and ≤ Grade 2 neuropathy are an exception to this criterion and qualify for the study.
  • Patients with recent major surgery in the previous 14 days prior to starting therapy must have recovered adequately from the toxicity and/or complications from the intervention.
  • Prior active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  • Active central nervous system (CNS) and/or carcinomatous meningitis, other than previously treated who are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment) and must be either off corticosteroids or on a stable or decrease dose ≤10 mg daily prednisone (or equivalent).
  • Presence of interstitial lung disease or history of pneumonitis requiring treatment with corticosteroids.
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    single-arm trial of Nivolumab

    Multi-institutional, single arm phase II trial with Simon's optimal two-stage design, to evaluate the clinical benefit of Nivolumab monotherapy in patients with platinum-recurrent or platinum-refractory metastatic GCT. No randomization or blinding is involved.

    Drug: Nivolumab

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Rate (CBR, %)

    number of patients with confirmed responses of a. complete responses (CR), disappearance of all imagiologic evidence of disease AND normalization of GCT tumor markers (αFP and HCG), or b. partial responses (PR) and stable diseases (SD) for at least 3 months, with stable, declining or normalized GCT tumor markers (αFP and HCG), divided by the total number of evaluable patients. Tumor response status will be assessed using RECIST 1.1.

    Time frame: 3 months

Secondary outcomes

  1. CR + marker-negative PR (%)

    number of patients with confirmed responses of a. complete responses (CR), disappearance of all imagiologic evidence of disease AND normalization of GCT tumor markers (αFP and HCG), or b. partial responses (PR) and stable diseases (SD) for at least 3 months, with stable, declining or normalized GCT tumor markers (αFP and HCG), divided by the total number of evaluable patients. Tumor response status will be assessed using RECIST 1.1.

    Time frame: 3 months

  2. CR + PR with stable or declining tumor markers (αFP and HCG)

    number of patients with confirmed responses of a. complete responses (CR), disappearance of all imagiologic evidence of disease AND normalization of GCT tumor markers (αFP and HCG), or b. partial responses (PR) and stable diseases (SD) for at least 3 months, with stable, declining or normalized GCT tumor markers (αFP and HCG), divided by the total number of evaluable patients. Tumor response status will be assessed using RECIST 1.1.

    Time frame: 3 months

  3. Time to response

    Median time (measured in months) to achieve a complete response, partial response or stable disease with stable, declining or normalized GCT tumor markers (αFP and HCG)

    Time frame: 6 months

  4. Duration of clinical response

    Median time (measured in months) since complete or partial response or stable disease with stable, declining or normalized GCT tumor markers (αFP and HCG) until progression

    Time frame: 24 months

  5. Progression Free Survival (PFS)

    Median survival time (measured in months) since the first administration of investigational drug until progression of the disease using RECIST 1.1.

    Time frame: 24 months

  6. Overall Survival (OS)

    Median survival time (measured in months) since the first administration of investigational drug until death.

    Time frame: 24 months

07

Study locations

1 site
  • Hospital Beatriz Ângelo
    Loures, 2674-514, Portugal
08

References and documents

Individual participant data

Plan to share: Yes — Clinical information will be shared with co-investigators

Supporting information: Study protocol, Informed consent form

Time frame: Data will be available for the intire study, 4 years

Access criteria: Only health professionals from Hospital Beatriz Ângelo, that make parte of the trial team will have acess

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jun 2019, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2018
First posted
Oct 31, 2018
StartActual
Oct 1, 2018
Primary completionActual
Jun 30, 2019
CompletionActual
Jun 30, 2019
Last update
Aug 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03726281
Lead sponsor
Hospital Beatriz Ângelo
Collaborators
Universidade Nova de Lisboa, Bristol-Myers Squibb, Instituto de Patologia e Imunologia Molecular da Universidade do Porto
Responsible party
Sponsor
First posted
Oct 31, 2018
Start date
Oct 1, 2018
Primary completion
Jun 30, 2019
Completion
Jun 30, 2019
Last update
Aug 21, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion